Featured Research

from universities, journals, and other organizations

How Much Progress Has There Been In Vaccinating Against Hib In The Americas?

Date:
April 22, 2008
Source:
Public Library of Science
Summary:
The bacterium Haemophilus influenzae type b (Hib) causes at least 3 million cases of severe disease each year, and about 400,000 children die annually due to pneumonia or meningitis caused by Hib. Vaccines against Hib are both safe and highly effective at reducing disease and deaths from Hib infection, and so the World Health Organization recommends the introduction of Hib vaccines worldwide.

The bacterium Haemophilus influenzae type b (Hib) causes at least 3 million cases of severe disease each year, and about 400,000 children die annually due to pneumonia or meningitis caused by Hib. Vaccines against Hib are both safe and highly effective at reducing disease and deaths from Hib infection, and so the World Health Organization recommends the introduction of Hib vaccines worldwide. In a policy paper in PLoS Medicine, M. Carolina Danovaro-Holliday (Pan American Health Organization; PAHO) and colleagues examine the progress of Hib vaccine introduction in the Americas.

Related Articles


They find that by the end of 2006, all countries of the Americas, except Haiti, had included Hib in their immunization schedule. Factors that favored this region-wide Hib vaccine adoption, they say, included strong political will, data supporting a high Hib disease burden and the positive impact of Hib vaccination in early adopters, and the existence of a mechanism called the Revolving Fund for bulk purchase of vaccines. But "efforts are still needed," say the authors, "to improve vaccination coverage and to strengthen invasive bacterial disease surveillance in developing countries."

Citation: Danovaro-Holliday MC, Garcia S, de Quadros C, Tambini G, Andrus JK (2008) Progress in vaccination against Haemophilus influenzae type b in the Americas. PLoS Med 5(4): e87

How will childhood pneumonia change if vaccine campaigns are a success?

In developing countries, two bacteria, pneumococcus and Hib, are the dominant causes of severe pneumonia in children. The introduction of vaccines against these diseases could reduce the global burden of severe pneumonia by about half. In this week's PLoS Medicine, J. Anthony G. Scott and Mike English--researchers at the Kenya Medical Research Institute--Wellcome Trust Collaborative Research Programme, Kenya--argue that the present classification and management guidelines for childhood pneumonia are founded on the dominance of these two organisms and will rapidly become obsolete as these vaccines are introduced.

The remaining cases of pneumonia, they say, will have a wide variety of causes and will include many cases of TB and noninfectious respiratory disease. This diversity of causes will make the diagnosis, classification, and management of pneumonia much more complex and expensive in the future. "To be relevant to future policy," say the authors, "research in the areas of pneumonia diagnosis, classification, prevention, or management should begin to anticipate this scenario now."

Citation: Scott JAG, English M (2008) What are the implications for childhood pneumonia of successfully introducing Hib and pneumococcal vaccines in developing countries? PLoS Med 5(4): e86.



Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Cite This Page:

Public Library of Science. "How Much Progress Has There Been In Vaccinating Against Hib In The Americas?." ScienceDaily. ScienceDaily, 22 April 2008. <www.sciencedaily.com/releases/2008/04/080422083322.htm>.
Public Library of Science. (2008, April 22). How Much Progress Has There Been In Vaccinating Against Hib In The Americas?. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2008/04/080422083322.htm
Public Library of Science. "How Much Progress Has There Been In Vaccinating Against Hib In The Americas?." ScienceDaily. www.sciencedaily.com/releases/2008/04/080422083322.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins